Back to Journals » Drug Design, Development and Therapy » Volume 11

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome

Authors Özdener AE, Rivkin A

Received 16 July 2017

Accepted for publication 1 September 2017

Published 26 September 2017 Volume 2017:11 Pages 2827—2840

DOI https://doi.org/10.2147/DDDT.S127405

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Qiongyu Guo

Ayşe Elif Özdener, Anastasia Rivkin

School of Pharmacy and Health Sciences, Fairleigh Dickinson University, Florham Park, NJ, USA

Abstract: Eluxadoline is a novel drug approved for the management of diarrhea predominant irritable bowel syndrome (IBS-D). It has unique pharmacology and works on three different opioid receptors. Several Phase II and III clinical trials have demonstrated eluxadoline’s efficacy in reducing symptoms related to IBS-D. Clinical trial results and postmarketing reports show a risk of pancreatitis in patients without a gallbladder or those abusing alcohol. This review article will include information on clinical trial results related to IBS-D management as well as eluxadoline’s limitations.

Keywords: IBS-D, eluxadoline, diarrhea, gastrointestinal, Viberzi

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]